
Claims

1. Use of an antibody-drug conjugate in the manufacture of a medicament for treating cancer, wherein
the antibody-drug conjugate and a tubulin inhibitor are to be administered in combination, and
the antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula is conjugated to the antibody via a thioether bond:



wherein A represents a connecting position to an antibody~~,~~
~~is conjugated to the antibody via a thioether bond~~;
wherein the antibody is an anti-HER2 antibody comprising a heavy chain consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of amino acid residues 1 to 214 of SEQ ID NO: 2, or wherein the antibody is an anti-HER2 antibody

comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2; and

wherein the tubulin inhibitor is paclitaxel, docetaxel, cabazitaxel, or a pharmacologically acceptable salt thereof; nab-paclitaxel; eribulin or a pharmacologically acceptable salt thereof; or an antibody-drug conjugate in which eribulin is conjugated to the antibody via a linker.

~~2. Use according to claim 1, wherein the antibody is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, an anti-GPR20 antibody, or an anti-CDH6 antibody.~~

~~3. Use according to claim 2, wherein the antibody is an anti-HER2 antibody.~~

~~4~~2. Use according to claim ~~3~~1, wherein the anti-HER2 antibody comprises a heavy chain consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of amino acid residues 1 to 214 of SEQ ID NO: 2.

~~5~~3. Use according to claim ~~3~~1, wherein the anti-HER2 antibody comprises a heavy chain consisting of an amino

acid sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2.

~~6~~4. Use according to any one of claims ~~3~~ 1 to ~~5~~3, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.

~~7. Use according to claim 2, wherein the antibody is an anti-HER3 antibody.~~

~~8. Use according to claim 7, wherein the anti-HER3 antibody comprises a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 3 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 4.~~

~~9. Use according to claim 7, wherein the anti-HER3 antibody comprises a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 3 in which a lysine residue at the carboxyl terminus of the heavy chain has been removed, and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 4.~~

~~10. Use according to any one of claims 7 to 9, wherein the average number of units of the drug-linker conjugated~~

~~per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~11. Use according to claim 2, wherein the antibody is an anti-TROP2 antibody.~~

~~12. Use according to claim 11, wherein the anti-TROP2 antibody comprises a heavy chain consisting of amino acid residues 20 to 470 of SEQ ID NO: 5 and a light chain consisting of amino acid residues 21 to 234 of SEQ ID NO: 6.~~

~~13. Use according to claim 11, wherein the anti-TROP2 antibody comprises a heavy chain consisting of amino acid residues 20 to 470 of SEQ ID NO: 5 from which a lysine residue at the carboxyl terminus of the heavy chain has been removed, and a light chain consisting of amino acid residues 21 to 234 of SEQ ID NO: 6.~~

~~14. Use according to any one of claims 11 to 13, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5.~~

~~15. Use according to claim 2, wherein the antibody is an anti-B7-H3 antibody.~~

~~16. Use according to claim 15, wherein the anti-B7-H3 antibody comprises a heavy chain consisting of amino acid residues 20 to 471 of SEQ ID NO: 7 and a light chain consisting of amino acid residues 21 to 233 of SEQ ID NO: 8.~~

~~17. Use according to claim 15, wherein the anti-B7-H3 antibody comprises a heavy chain consisting of amino acid residues 20 to 471 of SEQ ID NO: 7 from which a lysine residue at the carboxyl terminus of the heavy chain has been removed, and a light chain consisting of amino acid residues 21 to 233 of SEQ ID NO: 8.~~

~~18. Use according to any one of claims 15 to 17, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 3.5 to 4.5.~~

~~19. Use according to claim 2, wherein the antibody is an anti-GPR20 antibody.~~

~~20. Use according to claim 19, wherein the anti-GPR20 antibody comprises a heavy chain consisting of amino acid residues 20 to 472 of SEQ ID NO: 9 and a light chain consisting of amino acid residues 21 to 234 of SEQ ID NO: 10.~~

~~21. Use according to claim 19, wherein the anti-GPR20 antibody comprises a heavy chain consisting of amino acid residues 20 to 472 of SEQ ID NO: 9 from which a lysine residue at the carboxyl terminus of the heavy chain has been removed, and a light chain consisting of amino acid residues 21 to 234 of SEQ ID NO: 10.~~

~~22. Use according to any one of claims 19 to 21, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~23. Use according to claim 2, wherein the antibody is an anti-CDH6 antibody.~~

~~24. Use according to claim 23, wherein the anti-CDH6 antibody comprises a heavy chain consisting of amino acid residues 20 to 471 of SEQ ID NO: 11 and a light chain consisting of amino acid residues 21 to 233 of SEQ ID NO: 12.~~

~~25. Use according to claim 23, wherein the anti-CDH6 antibody comprises a heavy chain consisting of amino acid residues 20 to 471 of SEQ ID NO: 11 from which a lysine residue at the carboxyl terminus of the heavy chain has been removed, and a light chain consisting of amino acid residues 21 to 233 of SEQ ID NO: 12.~~

~~26. Use according to any one of claims 23 to 25, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.~~

~~27~~5. Use according to any one of claims 1 to ~~26~~4, wherein the tubulin inhibitor is paclitaxel, docetaxel, cabazitaxel, or a pharmacologically acceptable salt thereof, or nab-paclitaxel.

~~28~~6. Use according to claim ~~27~~5, wherein the tubulin inhibitor is paclitaxel.

~~29~~7. Use according to any one of claims 1 to ~~26~~4, wherein the tubulin inhibitor is eribulin or a pharmacologically acceptable salt thereof, or an antibody-drug conjugate in which eribulin is conjugated to the antibody via a linker.

~~30~~8. Use according to claim ~~29~~7, wherein the tubulin inhibitor is eribulin mesylate.

~~31~~9. Use according to any one of claims 1 to ~~30~~8, wherein the antibody-drug conjugate and the tubulin inhibitor are separately contained as active components in different formulations, and are to be administered simultaneously or at different times.

~~32~~10. Use according to any one of claims 1 to ~~31~~9, wherein the cancer is at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, salivary gland cancer, esophagogastric junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, and uterine carcinosarcoma.

~~33~~11. Use according to claim ~~32~~10, wherein the cancer is breast cancer.

~~34~~12. Use according to claim ~~32~~10, wherein the cancer is gastric cancer.

~~35~~13. Use according to claim ~~32~~10, wherein the cancer is lung cancer.

~~36~~14. Use according to claim ~~32~~10, wherein the cancer is ovarian cancer.